Jing Yan
He is an experienced neuroscientist and pioneered the discovery of our dual-acting NMDA receptor modulators and their role in depression.
His extensive experience in CNS research and drug development directly supports FundaMental Pharma’s mission to overcome barriers in treatment-resistant depression.
Jing Yan is a neuroscientist with over a decade of experience in CNS research, specialising in neurological diseases. His breakthrough discovery of the NMDAR/TRPM4 complex was published in Science and laid the scientific foundation for new therapeutic approaches.
His research has been distinguished with some of most prestigious scientific honors, including the Karl-Freudenberg-Preis of the Heidelberg Academy of Sciences, the Ruprecht-Karls-Preis of Heidelberg University and the IZN/Chica and Heinz Schaller Young Investigator Neuroscience Award.
Jing Yan earned his PhD in Neurobiology (summa cum laude) from Heidelberg University (Germany). He has published as first author in leading journals including Science, Cell Reports Medicine and Molecular Psychiatry and is an inventor on multiple granted and pending patents in the field of neurological diseases.
ArticleWhy NMDA receptor modulation remains central to next-generation depression therapies
A key player in brain communication and mood regulation, the pharmaceutical industry views the NMDAR as the central pillar for next-generation therapies for depression. Dirk Beher from FundaMental Pharma reveals new strategies for targeting this important receptor.